Abstract
Chronic high-fat diet consumption causes not only obese- insulin resistance, but also leads to pathological changes in salivary glands, including increased mitochondrial dysfunction, apoptosis, oxidative stress, and inflammation. Dipeptidyl peptidase-4 inhibitor (vildagliptin) is an oral anti-diabetic drug, using for treatment of type 2 diabetes. Vildagliptin has been shown to exert beneficial effects on several organs in cases of obese-insulin resistant condition. However, the effect of vildagliptin on salivary glands impaired by obese-insulin resistance has not been investigated. The hypothesis in this study is that vildagliptin confers beneficial effects on the salivary gland impaired by obese-insulin resistance via decreasing mitochondrial dysfunction, apoptosis, oxidative stress, and inflammation. Twenty-four male Wistar rats were divided into two groups. Each group was fed with either a normal (ND; n=8) or a high fat diet (HFD; n=16) for 16 weeks. At week 13, the HFD-fed rats were subdivided into 2 subgroups to receive either a vehicle or vildagliptin (3mg/kg/day) for 28days via gavage feeding. ND-fed rats were treated with the vehicle. At the end of treatment, metabolic parameters were examined, and rats were killed. Sub...Continue Reading
References
Jan 1, 1993·Science·G S HotamisligilB M Spiegelman
Feb 20, 1999·The Journal of Biological Chemistry·K M HeiskanenA L Nieminen
Dec 19, 2002·Free Radical Biology & Medicine·Timothy L DenningPeter B Ernst
Dec 16, 2004·The Journal of Clinical Investigation·Shigetada FurukawaIichiro Shimomura
Jul 21, 2006·Journal of Inflammation·Mayumi SuzukiAtsushi Nagai
Jun 30, 2010·Current Opinion in Endocrinology, Diabetes, and Obesity·Juan C Bournat, Chester W Brown
Jan 26, 2011·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Natheer H Al-Rawi
Feb 15, 2011·Life Sciences·Wasana PratchayasakulSiriporn C Chattipakorn
Nov 15, 2011·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Haixiang SuMervyn Gornitsky
Nov 24, 2011·Endocrinology·Noppamas PipatpiboonSiriporn C Chattipakorn
Apr 25, 2012·Life Sciences·Chontida YaranaSiriporn Chattipakorn
May 25, 2012·Endocrinology·Nattayaporn ApaijaiNipon Chattipakorn
Dec 18, 2012·The European Journal of Neuroscience·Noppamas PipatpiboonSiriporn C Chattipakorn
Mar 16, 2013·British Journal of Pharmacology·Nattayaporn ApaijaiNipon Chattipakorn
Mar 26, 2013·Journal of the American College of Cardiology·Seth S MartinSteven R Jones
Apr 18, 2013·The Journal of Endocrinology·Hiranya PintanaSiriporn C Chattipakorn
Apr 23, 2013·Journal of Dental Research·Y ShikamaM Funaki
May 3, 2013·Diabetologia·B A OmarB Ahrén
Oct 11, 2013·Oral Diseases·A ZalewskaH Car
Sep 10, 2014·Metabolism: Clinical and Experimental·Yan-ju WuLi-Ming Chen
Sep 18, 2014·Regulatory Peptides·Judit ÚjhelyiRóbert Pórszász
Oct 5, 2014·Archives of Medical Research·Jirapas SripetchwandeeSiriporn C Chattipakorn
Oct 7, 2014·Cardiovascular Drugs and Therapy·Nattayaporn ApaijaiNipon Chattipakorn
Dec 20, 2014·Handbook of Experimental Pharmacology·Peter VollenweiderChristian Widmann
Mar 22, 2015·Archives of Oral Biology·Lénia RodriguesElsa Lamy
Mar 31, 2015·Aging and Disease·Francesca BonominiRita Rezzani
Sep 12, 2015·Expert Opinion on Therapeutic Targets·Sana KhanAbul Kalam Najmi
Oct 10, 2015·Journal of Dental Research·M MulukeU Schulze-Späte
Feb 20, 2016·Metabolism: Clinical and Experimental·Shinichiro KimuraRyoichi Takayanagi
Apr 6, 2016·The Journal of Endocrinology·Nattayaporn ApaijaiNipon Chattipakorn
Jul 30, 2016·Journal of Diabetes Research·Jan MatczukKrzysztof Kurek
Dec 4, 2016·Diabetes Research and Clinical Practice·Ippei KanazawaToshitsugu Sugimoto